Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations

Genes Chromosomes and Cancer

Volumn 34, Issue 3, 2002, Pages 299-305

  Spitz, Ruediger ^a   Hero, Barbara ^a   Westermann, Frank ^b   Ernestus, Karen ^a   Schwab, Manfred ^b   Berthold, Frank ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LONG TERMINAL REPEAT; MONOSOMY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; SAMPLING; TUMOR SUPPRESSOR GENE;

ADULT; ALLELIC IMBALANCE; BONE MARROW NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; GENE AMPLIFICATION; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INTERPHASE; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; NEUROBLASTOMA; TREATMENT OUTCOME;

EID: 0036115740     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10070     Document Type: Article

References (26)

1. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: A 1 Mbp cosmid and PAC contig
2. The current contribution of molecular factors to risk estimation in neuroblastoma patients
3. Cytogenetic features of human neuroblastomas and cell lines
4. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
5. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: One probably imprinted, another associated with N-myc amplification
6. Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP
7. Clinical impact of chromosome 1 aberrations in neuroblastoma: A metaphase and interphase cytogenetic study
8. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma
9. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
10. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas
11. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma
12. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines
13. Chromosomal analysis of neuroblastoma
14. Disomy 1 with terminal 1p deletion is frequent in mass-screening- negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants
15. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
16. Comprehensive analysis of chromosome 1p deletions in neuroblastoma
17. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p
18. Amplification of oncogenes revisited: From expression profiling to clinical application
19. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma
20. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1
21. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma
22. There may be two tumor suppressor genes on chromosome arm lp closely associated with biologically distinct subtypes of neuroblastoma
23. Allelotype of neuroblastoma
24. Neuroblastoma consensus deletion maps to 1p36.1-2
25. Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma
26. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3